


HER2



HER2 inhibitors

Discovery	Cat.No.	Product Name	Information	Clinical Trial
2001	S1028	Lapatinib (GW-572016) Ditosylate	Targets HER2/ErbB2 IC ₅₀ (nM) 9.2	EGFR 10.8 Phase 2
2004	S2150	Neratinib (HKI-272)	Targets HER2 IC ₅₀ (nM) 59	EGFR 92 Phase 2
2010	S2192	AZD8931	Targets HER2/ErbB2 IC ₅₀ (nM) 3	EGFR 4 ErbB3 4 Phase 2
2006	S2216	Mubritinib (TAK 165)	Targets HER2/ErbB2 IC ₅₀ (nM) 6	Phase 2
2007	S1167	CP-724714	Targets HER2/ErbB2 IC ₅₀ (nM) 10	Phase 2
2008	S1011	Afatinib (BIBW2992)	Targets HER2 IC ₅₀ (nM) 14	EGFR ^{wt} 0.5 EGFR ^{L858R} 0.4 EGFR ^{L858R/T790M} 10 Phase 3
2001	S2111	Lapatinib	Targets HER2/ErbB2 IC ₅₀ (nM) 9.2	EGFR 10.8 Phase 2
2010	S1194	CUDC-101	Targets HER2 IC ₅₀ (nM) 15.7	EGFR 2.4 HDAC 4.4 Phase 1
2000	S1019	Canertinib (CI-1033)	Targets HER2/ErbB2 IC ₅₀ (nM) 9.0	EGFR 1.5 Phase 3
2004	S1486	AEE788 (NVP-AEE788)	Targets HER2/ErbB2 IC ₅₀ (nM) 6	EGFR 2 Phase 1/2
2006	S1056	AC480 (BMS-599626)	Targets HER2 IC ₅₀ (nM) 32	HER1 22 HER4 190 Phase 1